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Abstract
Introduction Current prescribing guidelines for the antipsychotic
amisulpride are based largely on pharmacokinetic (PK) studies in
young adults, and there is a relative absence of data on older
patients, who are at greatest risk of developing adverse events.
Methods This study aimed to develop a population PKmodel for
amisulpride specifically in older people, by combining data from a
richly sampled phase 1, single (50mg) dose study in healthy older
people (n = 20, 65–79 years), with a clinical dataset obtained
during off label, low-dose (25–75 mg daily) amisulpride prescrib-
ing in older people with Alzheimer’s disease (AD) (n = 25, 69–
92 years), as part of an observational study.
Results After introducing a scaling factor based on body weight,
age accounted for 20 % of the inter-individual variability in drug
clearance (CL), resulting in a 54%difference in CL between those
aged 65 and those aged 85 years, and higher blood concentrations
in older patients.
Discussion These findings argue for the consideration of age and
weight-based dose stratification to optimise amisulpride prescrib-
ing in older people, particularly in those aged 85 years and above.
Keywords Amisulpride . Elderly . Alzheimer’s disease .
Age . Population pharmacokinetics . Antipsychotic
Introduction
Safe and effective prescribing of antipsychotic medication is chal-
lenging in older people, as they are extremely susceptible to ad-
verse events, including extrapyramidal side effects (EPS), falls,
sedation and postural hypotension (Jeste et al. 2008; Leon et al.
2010). The mechanisms underpinning this heightened sensitivity
are poorly understood (Uchida et al. 2009b), and research which
aims to establish pharmacokinetic (PK) and pharmacodynamic
(PD) contributions to clinical response and side effects in older
clinical populations will be a key step towards improving safety
profiles (Bigos et al. 2008a; Lotrich et al. 2006). This issue is
particularly pertinent for older people with dementia, in whom
excessivemorbidity and increased cerebrovascular mortality have
led to a restriction of antipsychotic use, and an emphasis on safety
monitoring, but no clear guidance on minimum clinically effec-
tive doses when antipsychotic drugs are prescribed off licence to
treat psychotic symptoms (Jennum et al. 2015;Maust et al. 2015).
The most widely held assumption is that age-related changes
in peripheral pharmacokinetics, including changes in body com-
position, and a reduction in hepatic metabolism and renal clear-
ance, lead to higher blood concentrations for a given drug dose
(Mangoni and Jackson 2004;Merle et al. 2005).However, studies
that have used a population approach (Duffull et al. 2011; Ette
et al. 2004) to investigate PK profiles of antipsychotic drugs in
older patients have shown that an age effect on drug clearance is
not generalizable across antipsychotics (Bigos et al. 2008b; Feng
et al. 2008), and emphasise the need to develop PK models for
individual drugs.
Amisulpride is a second-generation antipsychotic drugwidely
used for the treatment of schizophrenia (Mauri et al. 2014), and
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for which optimal dose (400–800 mg daily), and therapeutic
range of dopamine (D2/3) receptor occupancy (40–70 %), and
blood concentration (100–319 ng/ml) have been clearly
established (Hiemke et al. 2011; Lako et al. 2013; Sparshatt
et al. 2009). These recommendations are based largely on pa-
tients below the age of 65 years, withminimal data on those aged
80 years and above. Pharmacokinetic studies of amisulpride
(Coukell and Benfield 1996; Hamon-Vilcot et al. 1998;
Rosenzweig et al. 2002) describe rapid absorption following oral
administration, achieving peak plasma concentration (Cmax) af-
ter 1 h, and a second peak after 3 h, consistent with hepatobiliary
elimination. The drug has low bioavailability (48 %) and low
plasma protein binding (17 %) and is not a cytochrome P450
substrate. Amisulpride is eliminated unchanged in the urine
(elimination half-life (t½) 12 h) and has high renal clearance
(330 ml/min), suggestive of additional renal secretion (Dufour
and Desanti 1988), possibly via the organic cation transport
(OCT) system (Dos Santos Pereira et al. 2014; Jonker and
Schinkel 2004). PK data on healthy older people are limited to
a phase 1 study, which examined amisulpride PK characteristics
in the first 72 h following a single (50 mg) dose (Hamon-Vilcot
et al. 1998).
We have recently collected PK, [18F]fallypride D2/3 receptor
imaging and clinical outcome data in older patients with ADwho
were prescribed amisulpride (25–75 mg daily) off label to treat
psychotic symptoms, as part of an open observational study. To
maximise the potential utility of this dataset to inform safer pre-
scribing in AD, we aimed to use a population approach to estab-
lish the consistency and identify sources of variability in PK-PD
relationships. This analysis represents the first stage of model
development, with the following aims:
1. To develop a population PK model for amisulpride spe-
cifically for older people and AD, by combining the clin-
ical dataset with published data from the single (50 mg)
dose study
2. To investigate the contribution of physiological character-
istics to inter-individual variability in PK parameters
3. To use model outputs to simulate and predict amisulpride
dose-concentration relationships in people aged 65 years
and over.
Methods
Data sources
Group 1
Twenty healthy elderly participants participated in a two-centre
open study, which was approved by the Ethics Committee of the
Pitie Salpetriere Hospital (Paris) (Hamon-Vilcot et al. 1998).
Participants were included on the basis of having no haemato-
logical or biochemical abnormalities and were on no concomi-
tant medication. Verbal and written informed consent was ob-
tained prior to inclusion. Participants were sampled before and at
1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 32, 48 and 72 h following a single
tablet of 50 mg amisulpride, administered in the morning.
Bloods concentrations of the amisulpride racemate were mea-
sured using a validated HPLC method based on liquid-liquid
extraction and fluorescence detection. Themethod is linear from
0.5 ± 640 ng/ml in plasma, with a limit of quantification of
0.5 ng/ml. Both the racemate and enantiomers of amisulpride
were measured, but only data on the racemate was used in the
current analysis, for consistency with group 2 data.
Group 2
PK data were obtained from 25 patients with a diagnosis of
probable AD (McKhann et al. 1984), who were participating in
an observational study of amisulpride prescribing in older people.
Patients were recruited from older adult mental health services
based within the catchment area of the South London and
MaudsleyNHSFoundation Trust (SLaM) (London, UK), imme-
diately prior to commencing low-dose amisulpride, which was
being used off label to treat psychotic symptoms. Exclusion
criteria included current or past history of psychiatric illness,
being prescribed an antipsychotic or other oral drug that inter-
feres with brain dopamine function, parkinsonian or other fea-
tures suggestive of Lewy Body Dementia (McKeith et al. 1996),
significant cardiorespiratory disease or needle phobia, and any
contraindication to amisulpride use as stated in the summary of
product characteristics (SmPc). Verbal andwritten informed con-
sent was obtained from participants, or from a carer where a
participant lacked capacity to give fully informed consent. The
study was approved by the Berkshire Research Ethics
Committee (REC reference 11/SC/0486). Clinical assessment
was carried out at baseline and during dose titration: Psychotic
symptoms and associated agitation were rated using the summed
total score on three domains (delusions, hallucinations and agi-
tation) of the carer-rated Neuropsychiatric Inventory (NPI)
(Cummings et al. 1994), and extrapyramidal symptoms (EPS)
were rated using the Simpson-Angus Scale (SAS) (Simpson and
Angus 1970). Where possible, [18F]fallypride dopamine D2/3
receptor positron emission tomography (PET) imaging was car-
ried out prior to amisulpride being commenced and when an
optimum dose was achieved (25 % reduction in symptoms).
Patients commenced amisulpride at a dose of 25 or 50mg (based
on the preference of the prescribing clinician), which was admin-
istered as a single evening dose, and increased to an optimum
dose (25 % or greater reduction in symptoms and minimal EPS).
Flexibility was built into the design around the timing of follow-
up assessments, to account for variability in the dose titration
regimen across prescribers and ensure that amisulpride concen-
trationwas obtained prior to each dose increase. As sampleswere
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taken at least 1 week after commencing amisulpride, all samples
were assumed to be at steady state. In compliance with medica-
tion (pill counts and discussion with carer), changes in concom-
itant medication and clinical outcome (symptom ratings, side
effects) were recorded at each visit. The timing of blood collec-
tion was not controlled and reflected convenience samples,
which coincided with follow-up assessments and/or imaging.
Date, time of sample and hours since last dose (confirmed by a
carer where possible) were recorded on the anonymised assay
request form. Blood samples were analysed in a secure, CPA-
accredited laboratory (Clinical Toxicology Unit, Kings College
Hospital). Amisulpride (racemate) blood concentrations were de-
termined using validated liquid chromatography with tandem
mass spectrometry (LC-MS/MS) method, with a detection limit
of 9 ng/ml.
Statistical analysis
Data were analysed using SPSS (version 22.0). Gender differ-
ences in demographic and physiological characteristics were
explored using independent samples t tests. Correlations were
expressed as Pearson’s correlation coefficient r.
Population PK analysis
Nonlinear mixed effects modelling (NLME) was implement-
ed using Monolix software (version 4.33; www.lixoft.eu).
Diagnostic graphics and tests for covariate screening were
performed in R. (version 3.2.4). Parameters were estimated
using the Stochast ic Approximation Expectat ion
Minimisation (SAEM) algorithm (Kuhn and Lavielle 2005).
Structural PK model
An oral two-compartment model was developed for
amisulpride, with five parameters: (i) an absorption constant
(ka), (ii) a central compartment (V1), representing blood and
well-perfused tissues (e.g. liver, kidney), (iii) a peripheral
compartment (V2) representing less well-perfused tissues
(e.g. muscle, lean tissue, fat), (iv) an inter-compartmental dis-
tribution constant (Q), and (v) an elimination constant (CL),
which includes renal and systemic clearance. The PK model
was initially described using data from the single dose study
(group 1), with initial estimates for the parameters being guid-
ed by the literature (Coukell and Benfield 1996; Hamon-
Vilcot et al. 1998; Rosenzweig et al. 2002). Group 1 data
was then combined with steady state data from AD patients
(group 2). Blood concentration was converted from nano-
grams per millilitre to milligrams per litre for use in PK model
building and concentrations below the limit of quantification
(LOQ 5e-4 mg/l for group1 and 9e-3 mg/l for group 2)
accounted for through simulation of the censored data with a
truncated Gaussian distribution in the SAEM-Markov Chain
Monte Carlo procedure (Samson and Lavielle 2006). Inter-
individual variability (IIV) for PK parameters was estimated
using an exponential model Pi = PTV × e
ηpi where Pi and ηpi
are the parameter estimate and corresponding random effect
for the ith individual, and PTV is the typical value for the
parameter at the population level. The variability between
the ith individual and population parameter values was de-
scribed by ηpi, which was assumed to be normally distributed
with a mean of 0 and a variance of ωp
2. In addition to IIV, a
proportional residual error model (yij = ŷij (1 + εij)) was used to
describe random unexplained variability (system noise, dos-
age history errors and/or model misspecifications), where yij
and ŷij represent the jth observed amisulpride concentration of
the ith subject, and its corresponding model predicted concen-
tration, and εij was assumed to be normally distributed with a
mean of 0 and a variance of σ2. Residual error was modelled
separately for each group, to account for inter-study
differences.
Covariate model
The contribution of physiological characteristics to IIV was
assessed in a covariate screening which included weight,
height, age and gender, and creatinine clearance (CrCL),
which was estimated using the Cockcroft and Gault equation
(Cockcroft and Gault 1976) and converted to l/h. Given the
co-linearity between CrCL and other covariates of interest
(weight, gender, age), serum creatinine was included as a sep-
arate covariate and allometric scaling for weight was intro-
duced as an initial step. For group 1, clearance parameters
(CL, Q) were set proportional to the body weight ratio over
70 kg to the power 0.75, and on the volume parameters (V1,
V2) proportional to the body weight ratio over 70 kg to the
power 1 (Mould et al. 2002). Covariates were then added in a
stepwise procedure after visual inspection of covariate plots
(continuous covariates were excluded if the correlation coef-
ficient r between covariate and parameter was <0.25) and
regression analysis in R. Continuous covariates which passed
initial screening were introduced into the model after log
transforming and centering on the mean. Gender was included
as a categorical covariate. For the combined dataset, the ab-
sence of data on early time points meant that it was necessary
to restrict allometric scaling for weight, and subsequent covar-
iate testing, to CL.
Model evaluation
Appropriateness of structural and covariate models was eval-
uated using goodness-of-fit criteria including diagnostic scat-
ter plots, visual predictive checks, degree of shrinkage, change
in IIV, model precision and likelihood ratio tests, with a 5 %
threshold.
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Model predictions
Population estimates for CL (CLTV) and effect size of covar-
iates (age and weight) on CL were used to estimate CL in an
individual (CLi), for a given age and weight, using the equa-
tion:
CLi ¼ CLTV* agei=meanageð Þβage;CL  weighti=70ð Þ0:75
Terminal half-life (t½) was calculated as the ratio of log (2)
and the second slope of elimination in the two-compartment
model, itself derived from clearances and volumes population
estimates.
Model simulations
One hundred people were simulated for amisulpride concen-
tration 15 h post-dose in each of the following categories: 65,
75 or 85 years; and of standard (70 kg) or low (50 kg) body
weight, across the prescribed dose range (25, 50, 75mg daily).
Results
Sample characteristics
Group 1
A total of 280 samples (14 per person) were obtained from 20
healthy elderly participants (10 men, mean age = 68.7 ± 4.1),
over 72 h following a single oral 50-mg dose of amisulpride.
Physiological characteristics of the sample are described in
Table 1. Weight (p < 0.01), height (p < 0.01) and serum cre-
atinine (p < 0.05) were significantly higher in men. CrCL was
correlated with weight (r = 0.53, p < 0.05) and creatinine
(r = −0.52, p < 0.05) but not age (r = −0.32, p = 0.16). A
scatterplot of observed amisulpride blood concentration (mg/
l) versus time (hours) since dose is shown in Fig. 1a. Cmax
(64.0 ± 29.9 ng/ml) was observed after 2.1 ± 0.78 h. Cmax
was higher in women (77.5 ± 28.8 ng/ml) than men
(50.5 ± 25.4 ng/ml) (p < 0.05), but not correlated with age
(r = −0.11, p = 0.64), height (r = −0.33, p = 0.15), weight
(r = −0.33, p = 0.15) or CrCL (r = −0.17, p = 0.48).
Group 2
A total of 41 samples (mean = 2 ± 0.78) were taken from 25
patients with AD (8(32 %) male; mean age = 82 ± 6.6 years
mean Mini Mental State Examination (MMSE) = 18.4 ± 5.4)
(Folstein et al. 1975), at 16.2 ± 3.1, over a dose range of 25–
75 mg daily. All samples were taken at steady state and after
56.9 ± 58-day treatment. Physiological and clinical character-
istics of AD patients are described in Table 2. Height
(p < 0.05) and serum creatinine (p < 0.05) were higher in
men. CrCL was significantly correlated with age (r = −0.65,
p < 0.01), weight (r = 0.65, p < 0.01) and serum creatinine
(r = −0.57, p < 0.01). A scatterplot showing observed
amisulpride concentration (mg/l) versus time (h) since dose
is shown in Fig. 1b. There was wide (>10-fold) variability in
dose-corrected concentration (mean = 0.85 ± 0.53 ng/ml),
which was correlated with age (r = 0.38, p = 0.01), but not
weight (r = −0.04, p = 0.81), or CrCL (r = 0.05, p = 0.77), with
no gender differences (p = 0.88).
PK model
Group 1
An oral two-compartment model (parameterised in ka, CL,
V1, Q, V2), which incorporated significant correlations for
Table 1 Physiological
characteristics: group 1 (healthy
elderly, single 50 mg dose)
Variable Mean ± SD
Total sample (n = 20)
Mean ± SD
Men (n = 10)
Mean ± SD
Women (n = 10)
Age (years) 68.7 ± 4.1 70.4 ± 5.1 67 ± 1.3
CrCL (ml/min) 80.5 ± 17.5 86.3 ± 18.2 74.4 ± 15.3
Weight (kg) 66.6 ± 9.1 73.7 ± 5.3 ** 59.5 ± 6.1
BMI (kg/m2) 24.1 ± 2.4 25.2 ± 1.8 * 22.9 ± 2.5
Height (m) 1.7 ± 0.1 1.7 ± 0.5 ** 1.61 ± 0.5
Creatinine (μmol/l) 56 ± 10.2 61.1 ± 9.7 * 51. 0 ± 8.4
Cmax (ng/ml) 64.0 ± 29.9 50.5 ± 25.4* 77.5 ± 28.8
Tmax (hours) 2.1 ± 0.8 2.4 ± 0.7 1.8 ± 0.8
Values for men and women were compared using independent samples t tests)
CrCL estimated creatinine clearance (ml/min—converted to l/h for the purposes of model building), BMI body
mass index (kg/m2 ), Cmax peak plasma concentration (ng/ml—converted to mg/l for the purposes of model
building), Tmax time taken to achieve Cmax (hours)
*p < 0.05; **p < 0.01
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random effects between CL, Q, V1 and V2, was found to be
the best fit for the data (see supplementary text and figures
ESM_1, ESM_2). The model showed excellent precision, low
(<5 %) shrinkage on clearance and volume parameters, and
low (13%) residual unexplained variability. Gender alone was
a significant predictor of V1 (β_V1, gender = −0.52, p = 6.6e-
005). Parameter estimates for the final model are summarised
in Table 3, and visual predictive checks (VPC) shown in
Fig. 2a. Population estimates for V1 were 40 % lower in
women (399 l/h) than men (668 l/h), and estimated t½ (based
on a 70 kg person) was 13.6 h for women and 15.2 h for men.
Combined dataset
In the combined dataset, the population estimate for
CL (54.3 l/h) was lower than that described for group
1 alone (84 l/h), and IIV on CL was higher (56 % in
the combined, compared to 33 % in the group 1
dataset). Residual unexplained variability (RUV) was
also higher for group 2 (53 %) than group 1 (13 %),
and shrinkage was >45 % for all parameters apart from
CL (27 %). Age was identified as the only significant
contributor to IIV in CL (β_CL, age = −2.9, p = 2.3e-
7). Parameter estimates for the best fit model are shown
in Table 3, and VPCs are shown separately for group 1
(Fig. 2b) and group 2 (Fig. 2c). Based on population
PK parameters (in a person of standard 70 kg weight),
the impact of age was such that CL in those aged
85 years (41.8 l/h) was 54 % lower than those aged
65 years (91.1 l/h), and t½ extended from 12.4 to
22.7 h. Model simulations for amisulpride concentra-
tions 15 h post-dose, accounting for age and body
weight, are shown in Fig. 3.
Discussion
We have developed a population PK model for
amisulpride in the elderly by combining data on healthy
older people with a representative sample of AD pa-
tients, who were receiving low-dose amisulpride off la-
bel specifically to treat psychotic symptoms. The fact
that PK data in group 1 was collected at multiple time
points meant that it was possible to fully parameterise
an oral two-compartment PK model and carry out co-
variate testing on all clearance and volume parameters.
The final model explained 87 % of the variance in PK
profile with excellent precision and identified gender as
a significant contributor to the variability in central vol-
ume of distribution (V1). Gender differences in V1,
which led to a higher Cmax in women and longer esti-
mated t½ in men (15.3 h compared to 13.6 h in wom-
en), were not explained by differences in body mass, as
weight was accounted for in the model through the use
of allometric scaling, and height was compared against
gender as part of covariate screening and model
development.
The addition of group 2 data increased the estimated
inter-individual variability in drug clearance from 31 %
(group 1 data alone) to 56 % (combined sample). This
variability was accounted for by a significant effect of
age on drug clearance, consistent with but not solely
accounted for an age-related reduction in CrCL. The
magnitude of the effect was such that CL at 85 years
was 54 % lower than at 65 years, resulting in increased
concentrations for a given dose in older patients.
Whether the observed age effect represents primarily
an effect of age on excretion, secretion or possibly both
is unclear, but this warrants further investigation, as it
has implications for the prescribing of other OCT sub-
strates, such as clozapine (Haenisch et al. 2012), in
older patients. It will also be important to further ex-
plore the nature of the age effect on CL, as it is likely
that the effect of age increases exponentially across the
Fig. 1 Scatterplot showing time since dose versus observed amisulpride
concentration (mg/l) in group 1, following a single 50-mg oral dose (a),
and group 2, at steady state across a dose range of 25–75 mg daily (b).
Concentrations below the limit of the assay sensitivity are shown in red
(colour figure online)
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age spectrum, resulting in changes in CL of a higher
order of magnitude in the oldest individuals.
Introducing allometric scaling into the covariate mod-
el (Holford 1996; Mould et al. 2002) allowed CL to be
estimated across the wide range of observed weights in
the clinical dataset. Model simulations suggest that
steady state blood concentrations at 50 mg amisulpride
daily would increase from 30 to 85 ng/ml between the
ages of 65 and 85 years in a 70-kg person, and from 40
to 120 ng/ml in a person of low (50 kg) body weight.
These findings argue for the consideration of age- and
weight-based dose adjustments in older people.
Previously conducted clinical studies have shown an
increase in CL and extended t½ in patients with renal
impairment (Rosenzweig et al. 2002). As a result, a
50 % reduction in daily dose is advised in moderate
renal disease (GFR 30–60 ml/min) and a 66 % reduc-
tion in severe renal disease (GFR is 10–30 ml/min). The
PK model developed in this analysis included eight AD
patients with moderate renal disease, a common finding
in older patients, and one advantage of building the
model from a representative clinical dataset. Our find-
ings suggest that, for patients aged 65 years and above
who do not have severe renal impairment, age and
weight could be considered in place of renal status, to
guide dose reductions.
The published literature on amisulpride (Mauri et al.
2014; Sparshatt et al. 2009) has consistently reported
higher dose-corrected concentrations in women during
TDM, and it has been assumed that gender differences
in drug clearance contribute to this (Coukell and
Benfield 1996). However, data from the four large, nat-
uralistic studies which have contributed most to our un-
derstanding of amisulpride PK are comprised predomi-
nantly of patients below 65 years and include minimal
data on patients aged 80 years and above (Bergemann
et al. 2004; Muller et al. 2009, 2007, 2006). In the
current study, there were no gender differences in
dose-corrected concentrations at steady state, and neither
was there an impact of gender on the variability in CL.
Our findings suggest that, after the age of 65 years, no
additional dose adjustments are required on the basis of
gender, after accounting for age and body weight.
There are several limitations to the analysis, includ-
ing the relatively small sample size and sparse sam-
pling in the clinical study. This meant that it was not
possible to estimate within-subject (inter-occasion) var-
iability in CL, which reduced the predictive power of
the model and contributed to the high residual unex-
plained variability (53 %). It was beyond the scope of
the current analysis to examine the contribution of oth-
er covariates such as concomitant medication, as the
study was not powered to incorporate multiple categor-
ical variables into the covariate model. This is howev-
er balanced by the fact that amisulpride is not a
CYP450 substrate, which reduces the likelihood of
potential drug interactions, and patients who were be-
ing p re sc r ibed drugs known to in te r ac t wi th
amisulpride, including OCT substrates lithium and
clozapine (Bowskill et al. 2012), were excluded from
participation in the study. We cannot completely rule
out the possibility that changes in renal function
Table 2 Sample characteristics:
group 2 (Alzheimer’s disease,
steady state amisulpride
treatment)
Variable Mean ± SD
Total sample (n = 25)
Mean ± SD
Men (n = 9)
Mean ± SD
Women (n = 16)
Age (years) 81.8 ± 6.6 81.8 ± 7.7 81.8 ± 6.1
MMSE (maximum 30) 18.4 ± 5.4 19.8 ± 4.3 17.7 ± 5.8
CrCL (ml/min) 67.7 ± 17.3 67.8 ± 20.9 67.7 ± 17.4
Weight (kg) 68.0 ± 15.2 72.0 ± 8 65.8 ± 18
BMI (kg/m2) 26.5 ± 5.4 25.8 ± 1.8 26.9 ± 6.7
Height (m) 1.6 ± 0.1 1.7 ± 0.1* 1.6 ± 0.1
Creatinine (μmol/l) 83.1 ± 25.7 97.4 ± 31.3* 75.1 ± 18.5
Daily dose at time of sampling (mg) 49.4 ± 11.2 48.3 ± 6.4 48.1 ± 13.7
Time since dose (h) 16.2 ± 3.1 15.8 ± 3.2 16.3 ± 2.9
Days treatment, current dose 56.9 ± 58 62.6 ± 68.8 57.4 ± 56.8
Amisulpride concentration (ng/ml) 40.9 ± 27.1 41.5 ± 26.2 40.5 ± 28.1
Dose-corrected concentration (ng/ml/mg) 0.85 ± 0.53 0.87 ± 0.52 0.84 ± 0.54
Values for men and women were compared using independent samples t tests
MMSE Mini Mental State Examination, CrCL estimated creatinine clearance (ml/min—converted to l/h for the
purposes of model building, BMI bodymass index (kg/m2 ),Cmax peak plasma concentration (ng/ml—converted
to l/h for the purposes of model building
*p < 0.05
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through the course of treatment contributed to the ob-
served variability in CL, as additional monitoring of
renal function was not routinely carried out during
dose titration, and there was wide variability in length
of follow-up due to technical difficulties around the
imaging procedure. Compliance is another important
source of potential variability in blood concentration
and particularly relevant in cognitively impaired pa-
tients. As a result, compliance was carefully moni-
tored (caregiver report and tablet counts) and facili-
tated by the clinical team.
Despite the limitations of the AD dataset, it represents the
first PK data on amisulpride within the context of therapeutic,
steady state dosing in a clinical population who reached the
extreme end of the age spectrum. The magnitude of the
change indicates that therapeutic blood concentrations are
achieved at lower doses and that age and body weight could
be considered in place of renal status to guide dose adjust-
ments. Obtaining additional steady state data on elderly peo-
ple will help to further refine the model predictions regarding
gender, concomitant medications and co-morbid health con-
ditions, including pre-existing renal impairment.
Previous studies which have used a population approach to
explore PK profiles of psychotropic drugs in older AD pa-
tients have producedmixed findings. For example, PKmodels
developed using data from the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) trials for Alzheimer’s dis-
ease (AD) and schizophrenia (SZ) have shown a significant
effect of age on clearance of the active metabolite (9-OH
risperidone) of risperidone (Feng et al. 2008), whereas inter-
individual variability in olanzapine clearance was accounted
for by factors other than age (gender, smoking and African-
Table 3 Pharmacokinetic model
estimates for group 1 and the
combined (groups 1 and 2)
sample
Parameter (units) Group 1 (n = 20) Combined (n = 45)
Estimate RSE (%) Estimate RSE (%)
ka 0.87 14 0.85 16
Cl 84 7 54.3 8
β-Cl,weight 0.75 ne 0.75 ne
β-Cl,Age ne ne −2.9 (p = 2.3e-007)
V1 668 (Men) 15 455 13
399 (Women) 13
β-V1, weight 1 ne ne ne
β-V1,Gender −0.52 (p = 6.6e-005) 25 ne ne
Q 117 15 111 16
β-Q,weight 0.75 ne ne ne
V2 population 808 12 736 11
β-V2,weight 1 ne ne ne
Random effect
ω_ka% 37 21 48 24
ω_Cl% 31 16 36 16
ω_V1% 42 21 43 27
ω_Q% 61 19 63 20
ω_V2% 50 17 46 18
ω_Cl_V1% 73 19 73 23
ω_Cl_Q% 68 21 60 29
ω_V1_Q% 51 48 73 23
ω_Cl_V2% 60 25 66 22
ω_V1_V2% 97 9 90 16
ω_Q_V2% 54 33 60 30
Residual error
σ (group 1)% 13 5 13 6
σ (group 2)% – – 53 24
ka absorption constant, Cl apparent clearance from central compartment, V1 central volume of distribution, Q
intercompartmental clearance, V2 peripheral volume of distribution, ω inter-individual variability (expressed as a
percentage), σ residual unexplained variability (expressed as a percentage and separated on the basis of group),
weight log transformed and centred around a standard 70 kg weight, age log transformed and centred around the
mean, RSE relative standard error, ne not estimated
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Fig. 2 Visual predictive checks
(VPC): 95 % prediction intervals
around the 5th, 50th and 95th
percentiles are shown for the final
model after analysis of group 1
data alone, overlaid to group 1
observed 5th, 50th and 95th
percentiles (a), and after analysis
of the combined dataset overlaid
to group 1 observed 5th, 50th and
95th percentiles (b), and overlaid
to group 2 observed 5th, 50th and
95th percentiles (c)
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American race) (Bigos et al. 2008b). These data, and a recent
publication from the Citalopram in Alzheimer’s disease
(CitAD) study, which showed significant and clinically rele-
vant effects of age and gender on metabolic clearance of R-
but not S-citalopram (Akil et al. 2016), serve to emphasise the
importance of extending pharmacological modelling to repre-
sentative older clinical populations, to meaningfully refine
and optimise age- and disease-specific dose adjustments.
The very low doses of amisulpride prescribed to AD
patients in this study are considerably lower than those
used to treat psychotic symptoms in schizophrenia
(Hiemke et al. 2011; Sparshatt et al. 2009) and at the
lower end of the suggested efficacious dose range from
open label studies which have similarly prescribed
amisulpride off licence to treat patients with AD and
psychotic symptoms (50–200 mg) (Lim et al. 2006;
Mauri et al. 2006). This reflects the primary aim of
the study, which was to establish the minimum clinical-
ly effective dose required to reduce symptoms without
EPS. As a result, dose titration regimens commenced at
doses as low as 25 mg (half a tablet) and increased to
an optimum, based on response and side effect profile.
Of the 25 patients included in the study, only one
achieved a blood concentration (109 ng/ml) within the
therapeutic range recommended for the treatment of
positive symptoms in schizophrenia (Hiemke et al.
2011; Sparshatt et al. 2009). This suggests that either
patient were sub-optimally treated in the current study
or that the target therapeutic range is lower in older AD
patients, as a result of age- and/or disease-related chang-
es in central pharmacokinetics (Clark-Papasavas et al.
2014; Seeman 2014) or altered pharmacodynamics (neu-
rotransmitter, receptor or signal transduction level),
which lower the therapeutic D2/3 occupancy range
(Graff-Guerrero et al. 2015; Uchida et al. 2009a). This
will be investigated in future analyses, which will aim
to combine the PK model with data on D2/3 receptor
imaging and clinical outcome, to explore PK occupancy
profiles, establish the target concentration and D2/3 occupan-
cy range to avoid non-response and EPS, and further inform
AD-specific dose adjustments.
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